Immunotherapy for Advanced Liver Cancer

Hepatocellular Carcinoma Clinical Trial

— ALIVE  

Official title:

Phase II/III Randomized, Controlled Clinical Study of AlloStim(R) vs Physician's Choice in Asian Subjects With Advanced Hepatocellular Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05033522
• Other study ID #: MBI-003-LIVE
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: August 1, 2023
• Est. completion date: December 1, 2025

Study information

• Verified date: September 2023
• Source: Immunovative Therapies, Ltd.
• Contact: Preechanoot Aimruen
• Phone: +66 2 163 6430
• Email: preechanoot.a[@]clinixir.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, controlled multi-site, multi-national clinical trial conducted in Thailand and Malaysia for Asian adults (males or females), 18 years of age and older presenting with advanced HCC (BCLC stage C) including subjects with macrovascular involvement and/or extrahepatic spread (not eligible for TACE, surgery or locoregional treatment) with Child-Pugh stage A or B liver function. 150 subjects will be randomized 2:1 to AlloStim® immunotherapy vs Physician's Choice of Sorafenib, Lenvatinib or FOLFOX4.

Description:

A multi-national, randomized, controlled trial (RCT) with multiple sites selected in Asia (Malaysia and Thailand). Subjects with no prior treatments for BCLC stage C disease and presenting with Child-Pugh class A or B liver reserve to be randomized 2:1 to AlloStim® vs. Physician's Choice (PC). PC to be declared prior to randomization. PC allowed to be either sorafenib, levantinib or FOLFOX4. The world incidence of hepatocellular carcinoma (HCC) is highest in East and South East Asia, with nearly half of the all HCC cases and deaths globally occurring in China. In Asian countries, the main treatment options for early or intermediate HCC (BCLC class A and B) include surgical resection, ablation (e.g., RFA, ETOH, cryoablation), transarterial chemoembolization (TACE), radiation or systemic chemotherapy depending on liver function status. However, in the Asian-Pacific region it is estimated that up to 80% of patients present with unresectable, advanced HCC (BCLC Stage C) that are not eligible for locoregional therapy, surgery or TACE due to tumor size and/or vascular involvement. For these patients, the standard of care for over a decade has been sorafenib (Bayer, A.G.), a oral kinase inhibitor based on the results of a RCT (SHARP study) of 602 patients randomized to sorafenib vs. placebo. Median overall survival (OS) was 10.7 months for sorafenib and 7.9 months for placebo (p<0.05). The SHARP study included a Western population. A separate study in Asian patients (226 patients from China, South Korea and Taiwan) comparing sorafenib to placebo (Sorafenib-AP study) demonstrated a OS of 6.5 months for sorafenib compared to 4.2 months for placebo (p<0.05). The placebo OS difference between Asian and Western patients (4.2mo vs 7.9 mo) suggests a difference in the disease characteristics in the Asian population. One significant difference is that the Asian population has an increased prevalence of HBV compared to Western population which may contribute to the increased incidence of HCC and worse OS outcomes observed in Asian patients compared to Western patients. In Thailand and Malaysia sorafenib is not available to a majority of the population presenting with advanced HCC, both due to cost and toxicity profile. This study is designed to evaluate whether AlloStim ® immunotherapy will provide a survival benefit to this population with an improved quality of life compared to approved first line therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 1, 2025
• Est. primary completion date: August 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Males and females who are at least 18 years of age at time of enrollment

2. Histologically or cytologically documented advanced HCC (BCLC stage C) disease at diagnosis.

3. No prior treatment for BCLC class C disease.

4. Child-Pugh Class A or subset of Child-Pugh Class B

5. Performance status: ECOG < 2 with no deterioration over the previous 2 weeks

6. With or without positive HBV and/or HCV

7. With or without extrahepatic disease and with or without macrovascular invasion

8. Measurable enhancing disease in liver with at least one target lesion evaluable by mRECIST

9. Adequate hematological, liver and renal function as assessed by the following:

• Hemoglobin > 10.0 g/dl
• Platelet count > 75,000/µl
• ALT and AST < 5.0 x ULN
• Serum creatinine < 1.5

10. Women of child-bearing potential: negative pregnancy test

11. Patients of child producing potential: usage of contraception or avoidance of pregnancy measures while enrolled on study

12. Ability to understand the study, its inherent risks, side effects and potential benefits and ability to give written informed consent to participate

Exclusion Criteria:

1. Any prior cancer diagnosis (other than cured basal cell carcinoma, head and neck carcinoma in-situ, or superficial Ta, Tis, T1 bladder cancer) or concurrent cancer histologically different than HCC (e.g., cholangiocarcinoma).

2. Child-Pugh liver function combined score >9 (Class C or Class D)

3. Moderate uncontrolled or severe ascites (+3 on Child-Pugh calculator)

4. Clinical symptoms of hepatic decompensation or presence of hepatic encephalopathy

5. Severe stomach/esophageal varices requiring interventional treatment.

6. Unable to tolerate radiological contrast dye

7. Any prior experimental, approved or off-label treatment for HCC (including levantinib, nivolumab, duvalumab, tremelimumab, brivananib, cabozantinib or ramucircumab) or any approved or experimental procedures such as surgery, radiation or ablation.

8. Enrollment in any previous clinical trial for HCC

9. Any history of autoimmune disorder (type I, insulin-dependent diabetes allowed)

10. History of COPD or oxygen saturation <92% at room air

11. Any clinical condition requiring systemic steroids (inhaled steroids allowed) or any current immunosuppressive therapy or anti-epileptic drug therapy.

12. Known history of HIV infection

13. Clinically significant gastrointestinal bleeding within 30 days prior to study entry

14. History of cardiac disease: congestive heart failure > NYHA class 2; cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or Digoxin are permitted)

15. Uncontrolled hypertension (SBP >150 or DBP>90).

16. Active clinically serious infections (> grade 2 CTCAE version 5.0)

17. History of organ transplant or tissue allograft

18. Uncontrolled concurrent serious medical or psychiatric illness

19. Clinically apparent central nervous system metastases or carcinomatous meningitis

20. History of drug abuse or current alcohol abuse

21. History of blood transfusion reactions

22. Pregnant or lactating women

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Biological:
• AlloStim® immunotherapy
3 cycles of intradermal and intravenous administrations

Drug:
• FOLFOX regimen
Comparative arm: Physician Choice of FOLFOX4 chemotherapy
• Sorafenib
Comparative arm: Physician Choice of Sorafenib
• Lenvatinib
Comparative Arm: Physician's Choice of Levantinib

Locations

Country	Name	City	State
Malaysia	Sultanah Bahiyah Hospital	Alor Setar	Kedah
Malaysia	Sultan Ismail Hospital	Johor Bahru	Johor
Malaysia	Hospital Pulau Pinang	Pulau Pinang	George Town
Malaysia	Columbia Asia Bukit Rimau	Shah Alam	Selangor Darul Ehsan
Thailand	Siriraj Hospital	Bangkok Noi	Bangkok
Thailand	Prince of Songkla University (Songklanagarind Hospital)	Hat Yai	Songkhla
Thailand	Naresuan University Hospital	Phitsanulok	Tha Pho
Thailand	Ramathibodi Hospital	Ratchathewi	Bangkok

Sponsors (2)

Lead Sponsor	Collaborator
Immunovative Therapies, Ltd.	Mirror Biologics, Inc.

Countries where clinical trial is conducted

Malaysia,  Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival	the time from randomization till death	rom date of randomization until the date of death from any cause, assessed up to 48 months
Secondary	Quality of Life Survey	using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-Hepatobiliary Questionnaire (FACT-Hep)	weekly assessments from baseline to 28 weeks
Secondary	Time to Symptomatic Progression	To assess time to symptomatic progression (TTSP)	rom date of randomization weekly for up to 24 weeks until the date of first documented progression which ever comes first

External Links

•   sponsor website